Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC50292A
- Development stage
- Phase 1
- Lead developer
- China Resources Double-Crane Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DC50292A is an investigational small molecule drug being developed as an oral tablet for the treatment of advanced or metastatic solid tumors with methylthioadenosine phosphorylase (MTAP) deletion. It is currently under evaluation in Phase 1 clinical trials for its safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy in patients with MTAP-deficient cancers. The drug’s mechanism of action and molecular target have not been publicly disclosed; it is intended as a targeted therapy for patients whose tumors exhibit loss of MTAP, which is a common genetic alteration in certain difficult-to-treat cancers.
Beyond the preview
Go deeper on DC50292A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC50292A.